Abstract :
Long-acting injectable antipsychotics, also known as depots, were developed in the late 1960s as an attempt toimprove compliance and long-term management of schizophrenia. Despite their availability for over 30 years,guidelines for their use and data on patients for whom long-acting injectable antipsychotics are most indicated aresparse and vary considerably. A review of the perceived advantages and disadvantages of using long-acting injectableantipsychotics is provided in this article, as well as a review of the literature to update clinicians on the currentadvances of this therapeutic option to optimize compliance and long-term management of chronic schizophrenia.
